PRTG Stock Summary and Trading Ideas (Portage Biotech | NASDAQ:PRTG)

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Portage Biotech trades on the NASDAQ stock market under the symbol PRTG.

As of January 31, 2025, PRTG stock price declined to $4.41 with 14,215 million shares trading.

PRTG has a beta of 1.25, meaning it tends to be more sensitive to market movements. PRTG has a correlation of 0.01 to the broad based SPY ETF.

PRTG has a market cap of $4.94 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, PRTG traded as high as $239.80 and as low as $2.10.

PRTG has underperformed the market in the last year with a return of -75.0%, while the SPY ETF gained +25.4%. In the last 3 month period, PRTG fell short of the market, returning -20.5%, while SPY returned +5.3%. However, in the most recent 2 weeks PRTG has outperformed the stock market by returning +11.4%, while SPY returned +2.9%.

PRTG support price is $4.12 and resistance is $5.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRTG shares will trade within this expected range on the day.